| CELTIC THERAPEUTICS AND BELLUS HEALTH INITIATE CONFIRMATORY PHASE III CLINICAL ... - PR Newswire (press release) |
|
|
PR Newswire (press release) The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis. |